Focus Partners Advisor Solutions LLC Cuts Position in Bristol Myers Squibb Company $BMY

Focus Partners Advisor Solutions LLC reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 21.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 96,478 shares of the biopharmaceutical company’s stock after selling 25,929 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Bristol Myers Squibb were worth $5,559,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. State of Wyoming increased its holdings in shares of Bristol Myers Squibb by 115.1% in the 2nd quarter. State of Wyoming now owns 7,237 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 3,872 shares in the last quarter. Kelleher Financial Advisors boosted its holdings in Bristol Myers Squibb by 11.2% during the second quarter. Kelleher Financial Advisors now owns 3,625 shares of the biopharmaceutical company’s stock worth $209,000 after buying an additional 365 shares in the last quarter. Bellars Harris Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth about $5,392,000. GSA Capital Partners LLP acquired a new position in Bristol Myers Squibb during the second quarter worth about $1,665,000. Finally, Stoneridge Investment Partners LLC purchased a new position in Bristol Myers Squibb in the second quarter valued at about $539,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $64.71 on Tuesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.10. The business has a fifty day simple moving average of $59.75 and a 200-day simple moving average of $59.06. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market cap of $132.18 billion, a P/E ratio of 14.25, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the firm posted $1.46 EPS. The company’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BMY shares. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Raymond James Financial assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Bank of America lowered their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Finally, Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.